-- Company to host virtual investor event to
review updated data on May 25, 2023
at 5:30pm ET --
CAMBRIDGE, Mass., April 26,
2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc.
(NASDAQ: THRX) (Theseus or the Company), a clinical-stage
biopharmaceutical company focused on improving the lives of cancer
patients through the discovery, development, and commercialization
of transformative targeted therapies, today announced that initial
dose escalation data from the ongoing phase 1/2 study of THE-630 in
advanced gastrointestinal stromal tumors (GIST) were accepted for
online publication at the 2023 American Society of Clinical
Oncology (ASCO) Annual Meeting, taking place June 2-6, in Chicago,
Illinois.
The abstract selected for online publication was submitted on
February 14, 2023. On May 25, 2023, Theseus plans to host a virtual
investor event to present data with an updated cutoff date. The
data to be presented from the ongoing dose escalation study are
expected to include preliminary safety, pharmacokinetic (PK), and
clinical activity data through cohort 6, as well as an analysis of
circulating tumor DNA (ctDNA) data through cohort 5.
THE-630 is a pan-variant tyrosine kinase inhibitor (TKI) of the
receptor tyrosine kinase KIT, designed for patients with GIST that
have developed resistance to earlier lines of therapy. The primary
objectives of the phase 1 dose escalation portion of the study are
to evaluate the safety profile of THE-630, including the
determination of a recommended phase 2 dose (RP2D) in GIST patients
who have received imatinib and at least one other TKI. Secondary
objectives include determining the PK profile of THE-630, and to
characterize preliminary evidence of antitumor activity.
Virtual Investor Event
Theseus will host a virtual investor event to review these new
data on Thursday, May 25, 2023,
beginning at 5:30pm ET. The event
will be webcast live and can be accessed in the Events section of
the Company's investor relations website at ir.theseusrx.com.
A replay of the webcast will be archived and available for 30 days
following the event.
About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on
improving the lives of cancer patients through the discovery,
development, and commercialization of transformative targeted
therapies. Theseus is working to outsmart cancer resistance by
developing pan-variant tyrosine kinase inhibitors (TKIs) to target
all classes of cancer-causing and resistance mutations that lead to
clinically relevant variants in a particular protein in a given
type of cancer. Theseus' lead product candidate, THE-630, is a
pan-variant KIT inhibitor for the treatment of patients with
advanced gastrointestinal stromal tumors (GIST), whose cancer has
developed resistance to earlier lines of kinase inhibitor therapy.
Theseus is also developing THE-349, a fourth-generation, selective
epidermal growth factor receptor (EGFR) inhibitor for
C797X-mediated resistance to first- or later-line osimertinib
treatment in patients with non-small cell lung cancer (NSCLC), and
a pan-variant BCR-ABL inhibitor for the treatment of
relapsed/refractory chronic myeloid leukemia (CML) and newly
diagnosed Philadelphia
chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). For
more information, visit www.theseusrx.com.
Cautionary Statement Regarding Forward Looking
Statements
Certain statements included in this press release are not
historical facts but are forward-looking statements for purposes of
the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking
statements generally are accompanied by words such as "believe,"
"may," "will," "estimate," "anticipate," "expect," "plan,"
"predict," "potential," "seem," "outlook," "continue," "intend,"
and similar expressions that predict or indicate future events or
trends or that are not statements of historical matters, but the
absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include, but are
not limited to, statements regarding: Theseus' strategy, future
operations, prospects and plans; the structure and timing of its
preclinical studies and clinical trials, the timing for the
presentation of preliminary data for THE-630, and Theseus' plans
regarding the phase 1/2 dose escalation and expansion clinical
trial for THE-630.
Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
risks, uncertainties and other factors, including, but not limited
to: uncertainties inherent in preclinical studies and clinical
trials; risks and uncertainties regarding whether results from
preclinical studies and clinical trials will be predictive of the
results of future trials; risks related to the expected timing of
submissions to regulatory authorities; and other risks,
uncertainties and other factors such as those described from time
to time in the reports Theseus files with the Securities and
Exchange Commission (SEC), including Theseus' Form 10-K for the
year ended December 31, 2022 and
subsequent Quarterly Reports on Form 10-Q which are on file with
the SEC and available on the SEC's website at https://www.sec.gov/.
However, new risk factors and uncertainties may emerge from time to
time which may cause actual results to differ materially from those
anticipated or implied by the forward-looking statements in this
press release, and it is not possible to predict all risk factors
and uncertainties. Accordingly, readers are cautioned not to place
undue reliance on these forward-looking statements. Any
forward-looking statements contained in this press release are
based on the current expectations of Theseus' management team and
speak only as of the date hereof, and Theseus specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise,
except as required by law.
Media Contact
Christen
Baglaneas
Director, Corporate Communications & Investor Relations
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
Investor Contact
Josh
Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com
View original
content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-initial-dose-escalation-results-from-ongoing-phase-12-trial-of-the-630-accepted-for-online-publication-at-2023-asco-annual-meeting-301807591.html
SOURCE Theseus Pharmaceuticals